prophylactic treatments with either recombinant human interleukin-1 beta ( rhuil-1 beta ) or a muramyl dipeptide analog ( [ abu1 ] mdp ) enhanced the resistance of mice to systemic infection with candida albicans .
C0021753
recombinant
C0086418
human